Ropeginterferon alfa-2b (Besremi®)

Assessment Status Rapid Review Complete
HTA ID 23004
Drug Ropeginterferon alfa-2b
Brand Besremi®
Indication Ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.
Assessment Process
Rapid review commissioned 20/01/2023
Rapid review completed 15/03/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ropeginterferon alfa-2b compared with the current standard of care.